Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.